What is HC Wainwright’s Forecast for HOWL Q1 Earnings?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Werewolf Therapeutics in a research note issued on Friday, November 8th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.38) per share for the quarter. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.42) EPS and Q4 2025 earnings at ($0.43) EPS.

Werewolf Therapeutics Stock Down 2.3 %

Shares of NASDAQ HOWL opened at $2.15 on Monday. The stock has a 50-day moving average price of $2.27 and a two-hundred day moving average price of $2.93. Werewolf Therapeutics has a 12 month low of $1.66 and a 12 month high of $8.19. The company has a current ratio of 12.13, a quick ratio of 12.13 and a debt-to-equity ratio of 0.24. The company has a market cap of $93.96 million, a price-to-earnings ratio of -1.41 and a beta of 0.41.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in shares of Werewolf Therapeutics during the first quarter worth $10,922,000. Millennium Management LLC increased its holdings in Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after purchasing an additional 544,881 shares in the last quarter. Vanguard Group Inc. raised its position in Werewolf Therapeutics by 26.8% in the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after purchasing an additional 233,909 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Werewolf Therapeutics by 410.5% during the second quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock valued at $327,000 after purchasing an additional 107,900 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Werewolf Therapeutics by 119.8% during the first quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after purchasing an additional 94,212 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.